BCL2 and leukemia: Vitexin is suggested to serve as a therapeutic agent for the treatment of human leukemia, as it promoted the expression of cleaved caspase-3 and cleaved caspase-9 in leukemia cells and simultaneously reduced Bcl-2 expression and therefore induced apoptosis (Lee et al., 2012).